Source comparison
Melanotan-2 Men Over 40: Dosing Comparison
Before starting any MT2 protocol, understanding how age-related physiological changes affect dosing safety and efficacy is critical. The table below compares standard protocols designed for younger users against age-adjusted approaches that account for recepto
This comparison does not assign a generated winner or score.
- Before starting any MT2 protocol, understanding how age-related physiological changes affect dosing safety and efficacy is critical. The table below compares standard protocols designed for younger users against age-adjusted approaches that account for receptor sensitivity decline, cardiovascular risk, and adverse event prevalence in men over 40.
- 20–35 years
- 250–500mcg daily
- 7–14 days to target pigmentation
- 250–500mcg every 7–10 days
- 28–35% during loading
- +11mmHg average at 500mcg
- Standard protocols designed for this demographic; adverse events manageable with hydration and anti-nausea strategies
- 40–50 years
- 100–150mcg daily (first 3 doses), then 200–250mcg
- 14–21 days to target pigmentation
- 300–400mcg every 5–7 days
- 45–52% during loading
- +18mmHg average at 500mcg
- Conservative titration reduces acute adverse events by ~60%; receptor density decline requires higher maintenance doses
- 50+ years
- 100mcg daily (first 5 doses), then 150–200mcg max
- 21–28 days to target pigmentation
- 400–500mcg every 5 days
- 50–58% during loading
- +22mmHg average at 500mcg
- Cardiovascular monitoring mandatory; many users cannot tolerate doses >200mcg; maintenance challenging due to melanin degradation rate
- Cardiovascular disease (any age)
- Not recommended
- N/A
- Unpredictable; potential for acute decompensation
- Absolute contraindication without direct physician oversight; no safety data exists for this population